Global burden of trauma: Need for effective fracture therapies

Indian Journal of Orthopaedics

Volumn 43, Issue 2, 2009, Pages 111-116

  Mathew, George ^a   Hanson, Beate P ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Bone stimulation therapies; Fracture; Orthopedic community; Trauma

Indexed keywords

EID: 67649531539     PISSN: 00195413     EISSN: 19983727     Source Type: Journal    
DOI: 10.4103/0019-5413.50843     Document Type: Conference Paper

References (89)

1. Murray CJL, Lopez AD, editors. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge, MA: Harvard School of Public Health; 1996.
2. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL, editors. Global burden of disease and risk factors. New York: Washington, DC: World Bank; Oxford University Press; 2006.
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442.
4. Peden M, McGee K, Sharma G. The injury chart book: a graphical overview of the global burden of injuries. Geneva: World Health Organization; 2002.
5. Krug EG, Sharma GK, Lozano R. The global burden of injuries. Am J Public Health 2000;90:523-6.
6. Norton R, Hyder AA, Bishai D, Peden M. Unintentional injuries. In:Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P, editors. Disease control priorities in developing countries. 2nd ed. New York, NY: Washington, DC: World Bank; Oxford University Press; 2006. p. 737-54.
7. Gururaj G. Injuries in India: National Perspective Burden of Disease in India. National Commission on Macroeconomics and Health. Government of India; 2005. p. 325-47.
8. Joshipura MK, Shah HS, Patel PR, Divatia PA, Desai PM. Trauma care systems in India. Injury 2003;34:686-92.
9. Sethi AK, Tyagi A. Trauma untamed as yet. Trauma Care 2001;11:89-90.
10. Wegman F. Road accidents: worldwide a problem that can be tackled successfully! 1996; AIPCR Publication No. 13.01.B.
11. Brinker MR, O'Connor DP. The incidence of fractures and dislocations referred for orthopaedic services in a capitated population. J Bone Joint Surg Am 2004;86:290-7.
12. Damien CJ, ParsonsJR. Bone graft and bone graft substitutes: a review of current technology and applications. J Appl Biomater 1991;2:187-208.
13. Novicoff WM, Manaswi A, Hogan MV, Brubaker SM, Mihalko WM, Saleh KJ. Critical analysis of the evidence for current technologies in bone-healing and repair. J Bone Joint Surg Am 2008;90:85-91.
14. Boyan B, McMillan J, Lohmann CH, Ranly DM, Schwartz Z. Bone graft substitutes: basic information for successful clinical use with special focus on synthetic graft substitutes. In: Laurencin CT, editor. Bone graft substitutes. West Conshohocken, PA: ASTM International; 2003. p. 231-59.
15. Moore WR, Graves SE, Bain GI. Synthetic bone graft substitutes. ANZ J Surg 2001;71:354-61.
16. Parikh SN. Bone graft substitutes in modern orthopaedics. Orthopaedics 2002;25:1301-11.
17. Finkemeier CG. Bone-grafting and bone graft substitutes. J Bone Joint Surg Am 2002;84:454-63.
18. LeGeros RZ. Properties of osteoconductive biomaterials: calcium phosphates. Clin Orthop Relat Res 2002;395:81-98.
19. Shors EC. The development of coralline porous ceramic graft substitutes. In: Laurencin CT, editor. Bone graft substitutes. West Conshohocken, PA: ASTM International; 2003. p. 271-85.
20. Bucholz RW. Nonallograft osteoconductive bone graft substitutes. Clin Orthop Relat Res 2002;395:44-52.
21. Mattsson P, Larsson S. Calcium phosphate cement for augmentation did not improve results after internal fixation of displaced femoral neck fractures: a randomized study of 118 patients. Acta Orthop 2006;77:251-6.
22. Mattsson P, Alberts A, Dahlberg G, Sohlman M, Hyldahl HC, Larsson S. Resorbable cement for the augmentation of internally-fixed unstable trochanteric fractures. A prospective, randomized, multicentre study. J Bone Joint Surg Br 2005;87:1203-9.
23. Mattsson P, Larsson S. Unstable trochanteric fractures augmented with calcium phosphate cement. A prospective randomized study using radiostereometry measure fracture stability. Scand J Surg 2004;93:223-8.
24. Mattsson P, Larsson S. Stability of internally fixed femoral neck fractures augmented with resorbable cement. A prospective randomized study using radiostereometry. Scand J Surg 2003;92:215-9.
25. Cassidy C, Jupiter JB, Cohen M, Delli-Santi M, Fennell C, Leinberry C, Husband J, Ladd A, Seitz WR, Constanz B. Norian SRS cement compared with conventional fixation in distal radius fractures. A randomized study. J Bone Joint Surg Am 2003;85:2127-37.
26. Zimmermann R, Gabi M, Lutz M,Angermann P, Gschwentner M, Pechlaner S. Injectable calcium phosphate bone cement Norian SRS for the treatment of intraarticular compression fractures of the distal radius in osteoporotic women. Arch Orthop Trauma Surg 2003;123:22-7.
27. Sanchez-Sotelo J, Munuera L, Madero R. Treatment of fractures of the distal radius with a remodellable bone cement: a prospective, randomized study using Norian SRS. J Bone Joint Surg Br 2000;82:856-63.
28. Chapman MW, Bucholz R, Cornell C. Treatment of acute fractures with a collagen-calcium phosphate graft material. A randomized clinical trial.J Bone Joint Surg Am 1997;79:495-502.
29. Cornell CN, Lane JM, Chapman M, Merkow R, Seligson D, Henry S, et al. Multicenter trial of Collagraft as bone graft substitute. J Orthop Trauma 1991;5:1-8.
30. Trippel SB. Growth factors as therapeutic agents. Instr Course Lect 1997;46:473-6.
31. Barnes GL, Kostenuik PJ, Gerstenfeld LC, Einhorn TA. Growth factor regulation of fracture repair. J Bone Miner Res 1999;14:1805-15.
32. Einhorn TA. Enhancement of fracture-healing. J Bone Joint Surg Am 1995;77:940-56.
33. Lieberman JR, Daluiski A, Einhorn TA. The role of growth factors in the repair of bone. Biology and clinical applications. J Bone Joint Surg Am 2002;84:1032-44.
34. Yasko AW, Lane JM, Fellinger EJ, Rosen V, Wozney JM, Wang EA. The healing of segmental bone defects, induced by recombinant human bone morphogenetic protein (rh-BMP-2). A radiological, histological, and biomechanical study in rats. J Bone Joint Surg Am 1992;74:659-70.
35. Bostrom M, Lane JM, Tomin E, Browne M, Berberian W, Turek T, Smith J, Wozney J, Schildhauer T. Use of bone morphogenetic protein-2 in the rabbit ulnar non-union model. Clin Orthop Relat Res 1996;327:272-82.
36. Radomsky ML, Thompson AY, Spiro RC, Poser JW. Potential role of fibroblast growth factor in enhancement of fracture healing. Clin Orthop Relat Res 1998;(355 Suppl):S283-93.
37. Radomsky ML, Aufdermorte TB, Swain LD, Fox WC, Spiro RC, Poser JW. Novel formulation of fibroblast growth factor-2 in a hyaluronan gel accelerates fracture healing in nonhuman primates. J Orthop Res 1999;17:607-14.
38. Simpson AH, Mills H, Noble B. The role of growth factors and related agents in accelerating fracture healing. J Bone Joint Surg Br 2006;88:701-5.
39. Broderick E, Infanger S, Turner TM, Sumner DR. Depressed bone mineralization following high dose TGF-beta-1 application in an orthopaedic implant model. Calcif Tissue Int 2005;76:379-84.
40. Schmidmaier G, Wildemann B, Gabelein T, HeegerJ, Kandziora F, Haas NP, Raschke M. Synergistic effect of IGF-I and TGF-beta 1 on fracture healing in rats: single versus combined application of IGF-I and TGF-beta 1. Acta Orthop Scand 2003;74:604-10.
41. Deckers MM, van Bezooijen RL, van der Horst G, Hoogendaam J, van Der Bent C, Papapoulos SE, Lowik CW. Bone morphogenetic proteins stimulate angiogenesis through oeteoblast-derived vascular endothelial growth factor A. Endocrinology 2002;143:1545-53.
42. Kelpke SS, Zinn KR, Rue LW, ThompsonJA. Site specific delivery of acidic fibroblast growth factor stimulates angiogenic and osteogenic responses in vivo. J Biomed Mater Res 2004;71:316-25.
43. Bail HJ, Kolbeck S, Krummrey G, Schmidmaier G, Haas NP, Raschke MJ. Systemic application of growth hormone for enhancement of secondary and intramembranous fracture healing. Horm Res 2002;58:39-42.
44. Kolbeck S, Bail H, Schmidmaier G, Alquiza M, Raun K, Kappelgard A, et al. Homologous growth hormone accelerates bone healing: a biomechanical and histological study. Bone 2003;33:628-37.
45. NashTJ, HowlettCR, Martin C, Steele J Johnson KA, Hicklin DJ. Effect of platelet-derived growth factor on tibial osteotomies in rabbits. Bone 1994;15:203-8.
46. Friedlaender GE, Perry CR, Cole JD, Cook SD, Cierny G, Muschler GF, et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am 2001;83:S151-8.
47. Govender S, Csimma C, Genant HK, Valentin-Opran A, AmitY, Arbel R, et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and Fifty patients. J Bone Joint Surg Am 2002;84:2123-34.
48. Swiontkowski MF, Aro HT, Donell S, Esterhai JL, Goulet J, Jones A, et al. Recombinant morphogenetic protein-2 in open tibial fractures. A subgroup analysis of data combined from two prospective randomized studies. J Bone Joint Surg Am 2006;88:1258-65.
49. Giannoudis PV, Tzioupis C. Clinical applications of BMP-7: the UK perspective. Injury 2005;36:S47-50.
50. Zimmermann G, Moghaddam A, Wagner C, Vock B, Wentzensen A. Clinical experience with bone morphogenetic protein 7 (BMP 7) in nonunions of long bones. Unfallchirug 2006;109:528-37.
51. Bilic R, Simic P, Jelic M, Stem-Padovan R, Dodig D, van Meerdervoort HP, et al. Osteogenic protein-1 (BMP-7) accelerates healing of scaphoid non-union with proximal pole sclerosis. Int Orthop 2006;30:128-34.
52. Jones AL, Bucholz RW, Bosse MJ, Mirza SK, Lyon TR, Webb LX, et al. BMP-2 Evaluation in Surgery for Tibial Trauma-Allograft (BESTT-ALL) Study Group. Recombinant human BMP-2 and allograft compared with autogenous bone graft for reconstruction of tibial diaphyseal fractures with cortical defects. A randomized, controlled trial. J Bone Joint Surg Am 2006;88:1431-41.
53. Friedlaender GE, Perry CR, CoIe JD, Cook SD, Cierny G, Muschler GF, et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am 2001;83-A:S151-8.
54. Connolly J, Guse R, Lippeillo L, Dehne R. Development of an osteogenic bone-marrow preparation. J Bone Joint Surg Am 1989;71:684-91.
55. Connolly JF, Guse R, TiedemannJ, Dehne R. Autologous marrow injection as a substitute for operative grafting of tibial non unions. Clin Orthop Relat Res 1991;266:259-70.
56. Muschler GF, Boehm C, Easley K. Aspiration to obtain osteoblast progenitor cells from human bone marrow: the influence of aspiration volume. J Bone Joint Surg Am 1997;79:1699-709.
57. Hernigou P, Poignard A, Beaujean F, Rouard H. Percutaneous autologous bone-marrow grafting for nonunions. Influence of the number and concentration of progenitor cells. J Bone Joint Surg Am 2005;87:1430-7.
58. Hernigou P, Mathieu G, Poignard A, Manicom O, Beaujean F, Rouard H. Percutaneous autologous bone-marrow grafting for nonunions. Surgical technique.J Bone Joint Surg Am 2006;88:322-7.
59. Tiedemann JJ, Connolly JF, Strates BS, Lippiello L. Treatment of nonunion by percutaneous injection of bone marrow and demineralized bone matrix. An experimental study in dogs. Clin Orthop Relat Res 1991;268:294-302.
60. Cornell CN, Lane JM, Chapman M, Merkow R, Seligson D, Henry S, et al. Multicenter trial of Collagraft as bone graft substitute. J Orthop Trauma 1991;5:1-8.
61. Ferreira SD, Dernell WS, Powers BE, Schochet RA, Kuntz CA, Withrow SJ, et al. Effect of gas-plasma sterilization on the osteoinductive capacity of demineralized bone matrix. Clin Orthop Relat Res 2001;388:233-9.
62. Bae HW, Zhao L, Kanim LE, Wong P, Delamarter RB, Dawson EG. Intervariability and intravariability of bone morphogenetic proteins in commercially available demineralized bone matrix products. Spine 2006;31:1299-308.
63. Russell JL, BlockJE. Clinical utility of demineralized bone matrix for osseous defects, arthrodesis, and reconstruction: impact of processing techniques and study methodology. Orthopaedics 2004;22:524-31.
64. Carpenter JF, Pikal MJ, Chang BS, Randolph TW. Rational design of stable lyophilized protein formulations: some practical advice. Pharm Res 1997;14:969-75.
65. Martin GJ Jr, Boden SD, Titus L, Scarborough NL. New formulations of demineralized bone matrix as a more effective graft alternative in experimental posterolateral lumbar spine arthrodesis. Spine 1999;24:637-45.
66. Flamini S, Francesco A, Colafarina O, Cerulli Mariani P, Pizzoferrato R, Rughetti A. Autologous platelet gel for delayed union of tibial shaft treated with intramedullary nailing. Ital J Orthop Traumatol 2007;8:1-5.
67. Savarino L, Cenni E, Tarabusi C, Dallari D, Stagni C, Cenacchi A, et al. Evaluation of bone healing enhancement by lyophilized bone grafts supplements with platelet gel: a standardized methodology in patients with tibial osteotomy for genu varus. J Biomed Mater Res B Appl Biomater 2006;76:364-72.
68. Evans CH, Ghivizzani SC, Herndon JH, Wasko MC, Reinecke J, Wehling P, Robbins PD. Clinical trials in gene therapy of arthritis. Clin Orthop Relat Res 2000;{379 Suppl):S300-7.
69. Evans CH, Ghivizzani SC, Robbins PD. Orthopaedic gene therapy. Clin Orthop Relat Res 2004;429:316-29.
70. Evans CH, Ghivizzani SC, Herndon JH, Robbins PD. Gene therapy for the treatment of musculoskeletal diseases. J Am Acad Orthop Surg 2005;13:230-42.
71. Giannoudis PV, Tzioupis CC, Tsiridis E. Gene therapy in orthopaedics. Injury 2006;37:S30-40.
72. Ivkovic A, Pascher A, Hudetz D, Jelic M, Haspl M, Windhager R, Pecina M. Current concepts in gene therapy of the musculoskeletal system. Acta Chir Orthop Traumatol Czech 2006;73:115-22.
73. Phillips FM, Blot PM, He TC, Haydon RC. Gene therapy for spinal fusion. SpineJ 2005;5:250S-8S.
74. Egermann M, Schneider E, Evans CH, Baltzer AW. The potential for gene therapy for fracture healing in osteoporosis. Osteoporos Int 2005;16:S120-8.
75. Shen W, Li Y, Huard J. Musculoskeletal gene therapy and its potential use in the treatment of complicated musculoskeletal infection. Infect Dis Clin North Am 2005;19:1007-22.
76. Vervoordeldonk MJ, Tak PP. Gene therapy in rheumatic diseases. Best Pract Res Clin Rheumatol 2001;15:771-88.
77. Muschler GF, Nakamoto C, Griffith LG. Engineering principles of clinical cell-based tissue engineering. J Bone Joint Surg Am 2004;86-A:1541-58.
78. Pountos I, Jones E, Tzioupis C, McGonagle D, Giannoudis PV. Growing bone and cartilage. The role of mesenchymal stem cells. J Bone Joint Surg Br 2006;88:421-6.
79. Gamradt SC, Lieberman JR. Genetic modification of stem cells to enhance bone repair. Ann Biomed Eng 2004;32:136-47.
80. Dickson G, Buchanan F, Marsh D, Harkin-Jones E, Little U, McCaigue M. Orthopaedic tissue engineering and bone regeneration. Technol Health Care 2007;15:57-67.
81. Luyten FP, Dell'Accio F, De Bari C. Skeletal tissue engineering: opportunities and challenges. Best Pract Res Clin Rheumatol 2001;15:759-69.
82. Franceschi RT. Biological approaches to bone regeneration by gene therapy. J Dent Res 2005;84:1093-103.
83. Vinatier C, GuicheuxJ, Daculsi G, Layrolle P, Weiss P. Cartilage and bone tissue engineering using hydrogels. Biomed mater Eng 2006;l6:S107-13.
84. Kofron MD, Laurencin CT. Bone tissue engineering by gene delivery. Adv Drug Deliv Rev 2006;58:555-76.
85. Skripitz R, Aspenberg P. Parathyroid hormone- a drug for orthopaedic surgery? Acta Orthop Scand 2004;75:654-62.
86. Koester MC, Spindler KP. Pharmacologic agents in fracture healing. Clin Sports Med 2006;25:63-73.
87. Aspenberg P. Drugs and fracture repair. Acta Orthop 2005;76:741-8.
88. Aleksyniene R, Hvid I. Parathyroid hormone- possible future drug for orthopaedic surgery. Medicina (Kaunas) 2004;40:842-9.
89. Thomas T. Intermittent parathyroid hormone therapy to increase bone formation. Joint Bone Spine 2006;73:262-9.